About Aileron Therapeutics (NASDAQ:ALRN)
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALRN
CUSIPN/A
Phone617-995-0900
Debt
Debt-to-Equity RatioN/A
Current Ratio10.60%
Quick Ratio10.60%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.25 per share
Price / Book1.85
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees13
Outstanding Shares14,730,000
Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions
What is Aileron Therapeutics' stock symbol?
Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."
How were Aileron Therapeutics' earnings last quarter?
Aileron Therapeutics (NASDAQ:ALRN) posted its quarterly earnings results on Monday, April, 2nd. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.03. View Aileron Therapeutics' Earnings History.
What price target have analysts set for ALRN?
4 brokers have issued 12-month price objectives for Aileron Therapeutics' shares. Their predictions range from $19.00 to $20.00. On average, they expect Aileron Therapeutics' share price to reach $19.3333 in the next year. View Analyst Ratings for Aileron Therapeutics.
Who are some of Aileron Therapeutics' key competitors?
Some companies that are related to Aileron Therapeutics include Immune Design (IMDZ), NewLink Genetics (NLNK), Tetraphase Pharmaceuticals (TTPH), Newron Pharmaceuticals (NWPHF), BioXcel Therapeutics (BTAI), Zynerba Pharmaceuticals (ZYNE), Acer Therapeutics (ACER), Aldeyra Therapeutics (ALDX), Sierra Oncology (SRRA), Bellerophon Therapeutics (BLPH), Aeglea Bio Therapeutics (AGLE), Checkpoint Therapeutics (CKPT), BioDelivery Sciences International (BDSI), Adamis Pharmaceuticals (ADMP), Galectin Therapeutics (GALT), Affimed (AFMD), OncoMed Pharmaceuticals (OMED) and ContraFect (CFRX).
Who are Aileron Therapeutics' key executives?
Aileron Therapeutics' management team includes the folowing people:
- Joseph A. Yanchik III, Esq., President, Chief Executive Officer, Director
- Evan Lippman, Chief Financial Officer and Business Officer, Senior Vice President
- , Bio & Compensation -
- Manuel C. Aivado, Senior Vice President and Chief Medical Officer
- , Bio & Compensation -
- D. Allen Annis Ph.D., Vice President - Biophysical and Analytical Technologies
- , Bio & Compensation -
- Seth L. Harrison M.D., Director
When did Aileron Therapeutics IPO?
(ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
Has Aileron Therapeutics been receiving favorable news coverage?
News coverage about ALRN stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aileron Therapeutics earned a daily sentiment score of 0.09 on Accern's scale. They also gave news stories about the company an impact score of 46.32 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Aileron Therapeutics?
Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aileron Therapeutics' stock price today?
One share of ALRN stock can currently be purchased for approximately $6.00.
How big of a company is Aileron Therapeutics?
Aileron Therapeutics has a market capitalization of $86.05 million. The company earns $-22,600,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Aileron Therapeutics employs 13 workers across the globe.
How can I contact Aileron Therapeutics?
Aileron Therapeutics' mailing address is 281 ALBANY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-995-0900 or via email at [email protected]
MarketBeat Community Rating for Aileron Therapeutics (ALRN)
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe ALRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aileron Therapeutics (NASDAQ:ALRN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Aileron Therapeutics in the last 12 months. Their average twelve-month price target is $19.3333, suggesting that the stock has a possible upside of 222.22%. The high price target for ALRN is $20.00 and the low price target for ALRN is $19.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.3333 | $19.3333 | $19.3333 | $19.3333 |
| Price Target Upside: | 222.22% upside | 57.82% upside | 57.82% upside | 57.82% upside |
Aileron Therapeutics (NASDAQ:ALRN) Consensus Price Target History
Aileron Therapeutics (NASDAQ:ALRN) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Aileron Therapeutics (NASDAQ:ALRN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aileron Therapeutics (NASDAQ ALRN) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 7.62%
Aileron Therapeutics (NASDAQ ALRN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/19/2018 | Apple Tree Partners Ii Lp | Major Shareholder | Sell | 107,904 | $6.31 | $680,874.24 | |  |
| 1/9/2018 | Apple Tree Partners Ii Lp | Major Shareholder | Sell | 150,000 | $9.80 | $1,470,000.00 | | |
| 7/5/2017 | Cvf, Llc | Major Shareholder | Buy | 180,000 | $15.00 | $2,700,000.00 | | |
| 7/5/2017 | Lilly Ventures Fund I Llc | Insider | Buy | 250,000 | $15.00 | $3,750,000.00 | | |
| 7/5/2017 | Reinhard J Ambros | Director | Buy | 266,667 | $15.00 | $4,000,005.00 | | |
(Data available from 1/1/2013 forward)
Aileron Therapeutics (NASDAQ ALRN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Apple Tree Partners Ii Lp Sells 107,904 Shares of Aileron Therapeutics (ALRN) Stock
www.americanbankingnews.com - April 19 at 10:10 PM |
| Aileron Therapeutics (ALRN) Receives New Coverage from Analysts at Jefferies Group
www.americanbankingnews.com - April 16 at 10:54 PM |
| Bank of America Initiates Coverage on Aileron Therapeutics (ALRN)
www.americanbankingnews.com - April 16 at 10:22 PM |
| Canaccord Genuity Begins Coverage on Aileron Therapeutics (ALRN)
www.americanbankingnews.com - April 16 at 10:22 PM |
| Contrasting Aileron Therapeutics (ALRN) & Aeglea Bio Therapeutics (AGLE)
www.americanbankingnews.com - April 16 at 5:21 AM |
| Aileron Therapeutics (ALRN) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - April 13 at 3:29 AM |
 | Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia
finance.yahoo.com - April 11 at 5:19 PM |
| Aileron Therapeutics (ALRN) Expected to Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - April 7 at 9:23 PM |
| Analysts Offer Predictions for Aileron Therapeutics' Q1 2018 Earnings (ALRN)
www.americanbankingnews.com - April 6 at 6:48 AM |
| Aileron Therapeutics to Post FY2022 Earnings of ($0.01) Per Share, Jefferies Group Forecasts (ALRN)
www.americanbankingnews.com - April 5 at 8:46 AM |
| Aileron Therapeutics (ALRN) Expected to Post Q1 2018 Earnings of ($0.48) Per Share
www.americanbankingnews.com - April 5 at 8:37 AM |
| Brokers Set Expectations for Aileron Therapeutics' Q1 2019 Earnings (ALRN)
www.americanbankingnews.com - April 4 at 7:59 AM |
 | Aileron Therapeutics misses by $0.01
seekingalpha.com - April 3 at 8:35 AM |
| Aileron Therapeutics (ALRN) Issues Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - April 3 at 7:35 AM |
| Zacks: Aileron Therapeutics (ALRN) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 29 at 10:28 AM |
| Aileron Therapeutics Announces Expansion of Scientific Advisory Board
finance.yahoo.com - March 28 at 8:39 AM |
| Zacks: Aileron Therapeutics (ALRN) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - March 25 at 7:40 AM |
| Reviewing Aileron Therapeutics (ALRN) and Johnson & Johnson (JNJ)
www.americanbankingnews.com - March 23 at 5:16 AM |
| Zacks: Analysts Set $19.33 Price Target for Aileron Therapeutics (ALRN)
www.americanbankingnews.com - March 21 at 3:28 AM |
| Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors
finance.yahoo.com - March 19 at 8:33 AM |
| Brokerages Set $19.33 Target Price for Aileron Therapeutics Inc (ALRN)
www.americanbankingnews.com - March 6 at 11:50 AM |
| Brokerages Expect Aileron Therapeutics Inc (ALRN) to Announce ($0.46) EPS
www.americanbankingnews.com - February 19 at 1:32 AM |
| -$0.46 EPS Expected for Aileron Therapeutics Inc (ALRN) This Quarter
www.americanbankingnews.com - February 16 at 1:22 AM |
| Aileron Therapeutics Inc (ALRN) Given $19.33 Consensus Target Price by Brokerages
www.americanbankingnews.com - February 4 at 3:06 PM |
| Zacks: Analysts Expect Aileron Therapeutics Inc (ALRN) to Post -$0.46 Earnings Per Share
www.americanbankingnews.com - January 30 at 1:16 AM |
| Zacks: Aileron Therapeutics Inc (ALRN) Given $19.33 Consensus Target Price by Brokerages
www.americanbankingnews.com - January 20 at 9:36 PM |
| Aileron Therapeutics Inc (ALRN) Given $19.33 Average Price Target by Analysts
www.americanbankingnews.com - January 17 at 5:42 AM |
| Aileron Therapeutics Inc (ALRN) Given $19.33 Consensus Target Price by Analysts
www.americanbankingnews.com - January 13 at 1:58 PM |
| Brokerages Expect Aileron Therapeutics Inc (ALRN) to Post -$0.46 EPS
www.americanbankingnews.com - January 13 at 3:28 AM |
| Insider Selling: Aileron Therapeutics Inc (ALRN) Major Shareholder Sells 150,000 Shares of Stock
www.americanbankingnews.com - January 11 at 6:38 PM |
| Aileron Therapeutics (ALRN) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - January 10 at 5:26 PM |
| Zacks: Aileron Therapeutics Inc (ALRN) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 28 at 1:38 AM |
| Critical Analysis: Aileron Therapeutics (ALRN) versus The Competition
www.americanbankingnews.com - December 25 at 7:29 PM |
| Aileron Therapeutics Inc's Lock-Up Period To End on December 26th (NASDAQ:ALRN)
www.americanbankingnews.com - December 19 at 1:14 AM |
| Analysts Set $19.33 Price Target for Aileron Therapeutics Inc (ALRN)
www.americanbankingnews.com - December 13 at 7:54 AM |
| Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
finance.yahoo.com - December 11 at 6:02 PM |
| Zacks: Aileron Therapeutics, Inc. (ALRN) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - December 5 at 1:36 AM |
| Aileron Therapeutics, Inc. (ALRN) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - November 19 at 1:38 PM |
 | Aileron Therapeutics Is Now Oversold (ALRN)
www.thestreet.com - November 16 at 11:03 AM |
| Zacks: Brokerages Set $19.33 Price Target for Aileron Therapeutics, Inc. (ALRN)
www.americanbankingnews.com - November 15 at 5:08 AM |
| Research Analysts Issue Forecasts for Aileron Therapeutics, Inc.'s Q1 2018 Earnings (ALRN)
www.americanbankingnews.com - November 13 at 6:00 AM |
| William Blair Comments on Aileron Therapeutics, Inc.'s Q1 2018 Earnings (ALRN)
www.americanbankingnews.com - November 13 at 6:00 AM |
 | Aileron Therapeutics (ALRN) Announces Oral Presentations on Lead Product Candidate ALRN-6924 at ASH
www.streetinsider.com - November 2 at 2:16 AM |
| Aileron Therapeutics, Inc. (ALRN) Given $19.33 Consensus Target Price by Analysts
www.americanbankingnews.com - October 31 at 5:38 PM |
| Zacks: Analysts Set $19.33 Target Price for Aileron Therapeutics, Inc. (ALRN)
www.americanbankingnews.com - October 16 at 12:52 PM |
| Boston biotech developing obesity drug pulls down $120M in IPO
finance.yahoo.com - October 10 at 2:53 AM |
| Zacks: Aileron Therapeutics, Inc. (ALRN) Given $19.33 Average Price Target by Brokerages
www.americanbankingnews.com - October 7 at 6:50 PM |
| Aileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell Microcap Indexes
finance.yahoo.com - September 19 at 3:46 PM |
| Analysts Set $19.33 Target Price for Aileron Therapeutics Inc (ALRN)
www.americanbankingnews.com - September 18 at 6:38 PM |
 | TTOO Rallies For 2nd Day, SAGE's STATUS Flops, ICPT Warns Of Ocaliva Overdosing
www.nasdaq.com - September 13 at 4:56 PM |
Aileron Therapeutics (NASDAQ:ALRN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aileron Therapeutics (NASDAQ:ALRN) Income Statement, Balance Sheet and Cash Flow Statement
Aileron Therapeutics (NASDAQ ALRN) Stock Chart for Monday, April, 23, 2018
Loading chart…
